CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

NCT06482684 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: KTE-X19
DRUG: Ibrutinib

Sponsor

Christian Schmidt, MD

Collaborators

[object Object]